



(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/41 (2006.01)
A61K 31/00 (2006.01) A61K 31/4745 (2006.01)
A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2017/021440

(22) International Filing Date:

8 March 2017 (08.03.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/305,519 8 March 2016 (08.03.2016) US

(71) Applicant: LOS GATOS PHARMACEUTICALS, INC.

[US/US]; 20 South Santa Cruz Avenue, Suite 300, Los Gatos, CA 95030 (US).

(72) Inventors; and

(71) Applicants : LANGECKER, Peter [US/US]; 17610 Via Sereno, Monte Sereno, CA 95030 (US). STEIERT, Matthias [US/US]; 15655 Liberty Street, San Leandro, CA 94578 (US). HINO, Toshiaki [US/US]; 1786 Spruce St., Apt 109, Berkeley, CA 94709 (US). SCICINKSI, Jan [US/US]; 19546 Vineyard Lane, Saratoga, CA 95070 (US). PAULVANNAN, Kumarapandian [US/US]; 6974 Blue Hill Drive, San Jose, CA 95129 (US).

(74) Agent: SINGH, Sunil, K.; Syndicated Law PC, 503 Seaport Ct., Suite 102, Redwood City, CA 94063 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CAMPTOTHECIN DERIVATIVES AND USES THEREOF




Fig. 1

(57) Abstract: Provided herein are camptothecin derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, cancer using the compounds and pharmaceutical compositions disclosed herein.

CAMPTOTHECIN DERIVATIVES AND USES THEREOF

This application claims priority under 35 U.S.C. § 119 (e) from United States Provisional Application Serial No. 62/305,519 filed March 8, 2016, which is hereby incorporated by reference in its entirety.

5

FIELD

Provided herein are camptothecin derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, cancer using the compounds and pharmaceutical compositions disclosed herein.

10

BACKGROUND

Camptothecin (CPT), originally isolated from the Chinese tree *Camptotheca acuminata*, possesses potent antitumor properties due to its inhibition of topoisomerase I (Hsiang *et al.*, *J Biol Chem* 1985, 260, 4873; Layergne *et al.*, *Cancer Res* 1999, 59, 2939; Saltz *et al.*, *Lancet* 2003, 361, 2235). However, CPT exhibits several properties that severely limit its clinical application such as low aqueous solubility, (Lerchen *et al.*, *J Med Chem* 2001, 44, 4186; Klein *et al.*, *J Med Chem* 2003, 46, 190; Saltz *et al.*, *Id.*) high levels of protein binding and rapid inactivation through lactone ring hydrolysis. The insolubility of CPT has severely restricted its clinical application and has led to the development of several water-soluble congeners, which are in various phases of clinical trials or in the clinic (Potmesil, *Cancer Res* 1994, 54, 1431). Camptothecin undergoes a reversible, pH-dependent ring opening reaction between the active lactone (closed E-ring) and inactive carboxylate (open E-ring) form, which has also been shown to be toxic: Lactone hydrolysis is also enhanced by the specific binding and sequestration of the carboxylate form to various proteins, such as human serum albumin, in the biological matrix, which shifts the equilibrium further toward the carboxylate form. Thus, the clinical utility of CPT has been severely hindered by the hydrolytic instability of its E-lactone ring in blood serum. Additionally, considerable variability in the oral and


15

20

25

30

intravenous bioavailability of CPT suggests poor cellular and tumor uptake of unmodified CPT drugs (Sinka *et al.*, *J Control Release* 2004, 100, 275).




Structure of Camptothecin (CPT) in Lactone (1) and Carboxylate (2) Forms

5 The issues, above, are not limited to camptothecin but are also shared to
certain extent by many of the pharmacologically active derivatives of
camptothecin. Accordingly, what are needed are new compositions of new
analogs of camptothecin and camptothecin derivatives that allow greater stability
and delivery of active drugs, while maintaining high loading and concentrations
10 of the drug in the composition.

SUMMARY

Provided herein are camptothecin derivatives which address these and other needs. In one aspect, a compound of Formula (I) is provided:



15


(I)

or salts, hydrates or solvates thereof, wherein:

R₁ is hydrogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, -SiR₆R₇R₈, alkyl substituted with one or more SiR₆R₇R₈, -CH=NOR₁₃ or optionally R₁ and R₂ together with the atom to which they are connected form a 5, 6 or 7 membered cycloalkyl or cycloheteroalkyl ring or substituted cycloalkyl or cycloheteroalkyl ring;


- R₂ is hydrogen, alkyl, substituted alkyl, -NO₂ or -NH₂;
- R₃ is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, or -OR₉ or optionally R₃ and R₄ together with the atom to which they are connected form a 5, 6 or 7 membered cycloalkyl or cycloheteroalkyl ring or substituted cycloalkyl or cycloheteroalkyl ring
- R₄ is hydrogen or halogen;
- R₅ is alkyl, aryl, arylalkyl, acyl or -(L)_n-P;
- R₆, R₇ or R₈ are independently alkyl or arylalkyl;
- R₉ is hydrogen, alkyl, substituted alkyl, -C(O)R₁₀ -C(O)OR₁₀ or -C(O)NR₁₁R₁₂, -P or -(L)_n-P;
- R₁₀ is alkyl, substituted alkyl, arylalkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;
- R₁₁, R₁₂ and R₁₃ are independently alkyl, substituted alkyl, arylalkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl or optionally R₁₂ and R₁₃ together with the atom to which they are connected form a 5, 6 or 7 membered cycloheteroalkyl ring or substituted cycloheteroalkyl ring;
- L is a linker;
- P is a polymer; and
- n is 0 or 1;
- provided that when R₁, R₂, R₃ and R₄ are hydrogen that R₅ is not -Ph, -C₂H₅, -C₅H₁₁, -C₆H₁₃, -C₇H₁₅, -C₈H₁₇, -C₁₅H₃₁, -C₃H₆C≡CH, -C₃H₆C≡CH, -C₃H₆C=CH₂ or -C=CH(CH₃);
- provided that when R₁, R₃ and R₄ are hydrogen and R₂ is -NO₂ that R₅ is not -Ph or -C₅H₁₁;
- provided that when R₁, R₃ and R₄ are hydrogen, and R₂ is -NH₂ that R₅ is not -Ph, -C₅H₁₁ or -C₈H₁₇;
- provided that when R₁, R₂ and R₄ are hydrogen and R₃ is -OCH₃ that R₅ is not -C₂H₅ or -C₅H₁₁;
- provided that when R₂, R₃ and R₄ are hydrogen and R₁ is -CH₃ that R₅ is not -Ph or -C₆H₁₃;
- provided that when R₂, R₃ and R₄ are hydrogen and R₁ is -CH₂OH that R₅ is not -C₅H₁₁ or -C₆H₁₃;

provided that when R_2 , R_3 and R_4 are hydrogen and R_1



is that R_5 is not $-C_6H_{13}$;


provided that when R_2 , R_3 and R_4 are hydrogen and R_1



is that R_5 is not $-C_5H_{11}$;

5

provided that when R_2 , R_3 and R_4 are hydrogen and R_1



is that R_5 is not $-Ph$;

provided that when R_1 , R_2 and R_4 are hydrogen and R_3 is $-C(O)R_{10}$ that R_5 and R_{10} are not identical;

provided that when R_2 and R_4 are hydrogen, R_1 is $-C_2H_5$ and R_3 is -

10

$C(O)R_{10}$ that R_5 and R_{10} are not identical;

provided that when R_2 and R_4 are hydrogen, R_1 is $-C_2H_5$ and R_3 is $-H$ that R_5 is not $C_{10}H_{21}$; and

provided that when R_2 and R_4 are hydrogen, R_1 is $-C_2H_5$ and R_3 is -

$C(O)OtBu$ that R_5 is not $C_{10}H_{21}$.

15

Also provided are derivatives, including salts, esters, enol ethers, enol esters, solvates, hydrates and metabolites of the compounds described herein. Further provided are pharmaceutical compositions which include the compounds provided herein and a vehicle.

20

Methods of treating, preventing, or ameliorating symptoms of medical disorders such as, for example, cancer or infection, are also provided herein. In practicing the methods, therapeutically effective amounts of the compounds or pharmaceutical compositions thereof are administered to a subject.

DETAILED DESCRIPTION

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

“Alkyl” by itself or as part of another substituent, refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne. Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), cycloprop-1-en-1-yl; cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, *etc.*; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, *etc.*; and the like. The term “alkyl” is specifically intended to include groups having any degree or level of saturation, *i.e.*, groups having exclusively single carbon-carbon bonds, groups having one or more double carbon-carbon bonds, groups having one or more triple carbon-carbon bonds and groups having mixtures of single, double and triple carbon-carbon bonds. Where a specific level of saturation is intended, the expressions “alkanyl,” “alkenyl,” and “alkynyl” are used. In some embodiments, an alkyl group comprises from 1 to 20 carbon atoms (C₁-C₂₀ alkyl). In other embodiments, an alkyl group comprises from 1 to 10 carbon atoms (C₁-C₁₀ alkyl). In still other embodiments, an alkyl group comprises from 1 to 6 carbon atoms (C₁-C₆ alkyl).

“Alkanyl” by itself or as part of another substituent, refers to a saturated branched, straight-chain or cyclic alkyl radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Typical alkanyl

groups include, but are not limited to, methanyl; ethanyl; propanyls such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl, *etc.*; butanyls such as butan-1-yl, butan-2-yl (*sec*-butyl), 2-methyl-propan-1-yl (isobutyl), 2-methyl-propan-2-yl (*t*-butyl), cyclobutan-1-yl, *etc.*; and the like.

5 “Alkenyl” by itself or as part of another substituent, refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene. The group may be in either the *cis* or *trans* conformation about the double bond(s). Typical alkenyl groups include, but are
10 not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl; cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl,
15 cyclobuta-1,3-dien-1-yl, *etc.*; and the like.

 “Alkynyl” by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne. Typical alkynyl groups include, but are
20 not limited to, ethynyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, *etc.*; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, *etc.*; and the like.

 “Acyl” by itself or as part of another substituent refers to a radical -C(O)R⁴⁰⁰, where R⁴⁰⁰ is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl,
25 heteroarylalkyl or substituted heteroarylalkyl as defined herein. Representative examples include, but are not limited to formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like.

 “Aryl” by itself or as part of another substituent, refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from
30 a single carbon atom of a parent aromatic ring system, as defined herein. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene,

- acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, *as*-indacene, *s*-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene,
- 5 phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like. In some embodiments, an aryl group comprises from 6 to 20 carbon atoms (C₆-C₂₀ aryl). In other embodiments, an aryl group comprises from 6 to 15 carbon atoms (C₆-C₁₅ aryl). In still other embodiments, an aryl group comprises from 6 to 15 carbon atoms (C₆-C₁₀ aryl).
- 10 “Arylalkyl” by itself or as part of another substituent, refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or *sp*³ carbon atom, is replaced with an aryl group as, as defined herein. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl,
- 15 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, arylalkenyl and/or arylalkynyl is used. In some embodiments, an arylalkyl group is (C₆-C₃₀) arylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C₁-C₁₀) alkyl and the aryl moiety is (C₆-C₂₀) aryl. In other
- 20 embodiments, an arylalkyl group is (C₆-C₂₀) arylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C₁-C₈) alkyl and the aryl moiety is (C₆-C₁₂) aryl. In still other embodiments, an arylalkyl group is (C₆-C₁₅) arylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C₁-C₅) alkyl and the aryl moiety is (C₆-C₁₀) aryl.
- 25 “Compounds” refers to compounds encompassed by structural formulae disclosed herein and includes any specific compounds within these formulae whose structure is disclosed herein. Compounds may be identified either by their chemical structure and/or chemical name. When the chemical structure and chemical name conflict, the chemical structure is determinative of the identity of
- 30 the compound. The compounds described herein may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (*i.e.*, geometric isomers), enantiomers or diastereomers.

Accordingly, the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the illustrated compounds including the stereoisomerically pure form (*e.g.*, geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures.

- 5 Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan. The compounds may also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all
- 10 possible tautomeric forms of the illustrated compounds. The compounds described also include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that may be incorporated into the compounds described herein include, but are not limited to, ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O ,
- 15 ^{35}S , *etc.* In general, it should be understood that all isotopes of any of the elements comprising the compounds described herein may be found in these compounds. Compounds may exist in unsolvated or unhydrated forms as well as solvated forms, including hydrated forms and as N-oxides. In general, compounds may be hydrated, solvated or N-oxides. Certain compounds may
- 20 exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention. Further, it should be understood, when partial structures of the compounds are illustrated, that brackets indicate the point of attachment of the partial structure to the rest of the molecule.
- 25 “Heteroalkyl,” “Heteroalkanyl,” “Heteroalkenyl” and “Heteroalkynyl” by themselves or as part of other substituents, refer to alkyl, alkanyl, alkenyl and alkynyl groups, respectively, in which one or more of the carbon atoms (and optionally any associated hydrogen atoms), are each, independently of one another, replaced with the same or different heteroatoms or heteroatomic groups.
- 30 Typical heteroatoms or heteroatomic groups which can replace the carbon atoms include, but are not limited to, -O-, -S-, -N-, -Si-, -NH-, -S(O)-, -S(O)₂-, -S(O)NH-, -S(O)₂NH- and the like and combinations thereof. The heteroatoms or

heteroatomic groups may be placed at any interior position of the alkyl, alkenyl or alkynyl groups. Typical heteroatomic groups which can be included in these groups include, but are not limited to, -O-, -S-, -O-O-, -S-S-, -O-S-, -NR⁵⁰¹R⁵⁰²-, =N-N=, -N=N-, -N=N-NR⁵⁰³R⁵⁰⁴-, -PR⁵⁰⁵-, -P(O)₂-, -POR⁵⁰⁶-, -O-P(O)₂-, -SO-, -SO₂-, -SnR⁵⁰⁷R⁵⁰⁸- and the like, where R⁵⁰¹, R⁵⁰², R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵, R⁵⁰⁶, R⁵⁰⁷ and R⁵⁰⁸ are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl.

“Heteroaryl” by itself or as part of another substituent, refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring systems, as defined herein. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, β -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. In some embodiments, the heteroaryl group comprises from 5 to 20 ring atoms (5-20 membered heteroaryl). In other embodiments, the heteroaryl group comprises from 5 to 10 ring atoms (5-10 membered heteroaryl). Exemplary heteroaryl groups include those derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole and pyrazine.

“Heteroarylalkyl” by itself or as part of another substituent refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or *sp*³ carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylakenyl and/or heteroarylalkynyl is used. In some embodiments, the

heteroarylalkyl group is a 6-21 membered heteroarylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is (C₁-C₆) alkyl and the heteroaryl moiety is a 5-15-membered heteroaryl. In other embodiments, the heteroarylalkyl is a 6-13 membered heteroarylalkyl, *e.g.*, the alkanyl, alkenyl or
5 alkynyl moiety is (C₁-C₃) alkyl and the heteroaryl moiety is a 5-10 membered heteroaryl.

“Hydrates” refers to incorporation of water into to the crystal lattice of a compound described herein, in stoichiometric proportions, resulting in the formation of an adduct. Methods of making hydrates include, but are not limited to, storage in an atmosphere containing water vapor, dosage forms that include water, or routine pharmaceutical processing steps such as, for example, crystallization (*i.e.*, from water or mixed aqueous solvents), lyophilization, wet granulation, aqueous film coating, or spray drying. Hydrates may also be formed, under certain circumstances, from crystalline solvates upon exposure to water vapor, or upon suspension of the anhydrous material in water. Hydrates may also crystallize in more than one form resulting in hydrate polymorphism. See *e.g.*, (Guillory, K., Chapter 5, pp. 202-205 in *Polymorphism in Pharmaceutical Solids*, (Brittain, H. ed.), Marcel Dekker, Inc., New York, NY, 1999). The above methods for preparing hydrates are well within the ambit of those of skill in the art, are completely conventional and do not require any experimentation beyond what is typical in the art. Hydrates may be characterized and/or analyzed by methods well known to those of skill in the art such as, for example, single crystal X-ray diffraction, X-ray powder diffraction, Polarizing optical microscopy, thermal microscopy, thermogravimetry, differential thermal
15 analysis, differential scanning calorimetry, IR spectroscopy, Raman spectroscopy and NMR spectroscopy. (Brittain, H., Chapter 6, pp. 205-208 in *Polymorphism in Pharmaceutical Solids*, (Brittain, H. ed.), Marcel Dekker, Inc. New York, 1999). In addition, many commercial companies routine offer services that include preparation and/or characterization of hydrates such as, for example,
20 HOLODIAG, Pharmaparc II, Voie de l'Innovation, 27 100 Val de Reuil, France (<http://www.holodiag.com>).

“Parent Aromatic Ring System” refers to an unsaturated cyclic or polycyclic ring system having a conjugated π electron system. Specifically included within the definition of “parent aromatic ring system” are fused ring systems in which one or more of the rings are aromatic and one or more of the

5 rings are saturated or unsaturated, such as, for example, fluorene, indane, indene, phenalene, *etc.* Typical parent aromatic ring systems include, but are not limited to, aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, *as*-indacene, *s*-indacene, indane, indene, naphthalene, octacene,

10 octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like.

“Preventing” or “prevention” refers to a reduction in risk of acquiring a disease or disorder (*i.e.*, causing at least one of the clinical symptoms of the

15 disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease). In some embodiments, “preventing” or “prevention” refers to reducing symptoms of the disease by taking the compound in a preventative fashion. The application of a therapeutic for preventing or prevention of a disease or disorder is known as

20 ‘prophylaxis.’ In some embodiments, the compounds provided herein provide superior prophylaxis because of lower long term side effects over long time periods.

“Prodrug” refers to a derivative of a drug molecule that requires a transformation within the body to release the active drug. Prodrugs are

25 frequently (though not necessarily) pharmacologically inactive until converted to the parent drug.

“Promoiety” refers to a form of protecting group that when used to mask a functional group within a drug molecule converts the drug into a prodrug. Typically, the promoiety will be attached to the drug *via* bond(s) that are cleaved

30 by enzymatic or non-enzymatic means *in vivo*.

- “Salt” refers to a salt of a compound, which possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or
- 5 formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid,
- 10 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid,
- 15 stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, *e.g.*, an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. In some embodiments, the salt is pharmaceutically acceptable.
- 20 “Solvates” refers to incorporation of solvents into to the crystal lattice of a compound described herein, in stoichiometric proportions, resulting in the formation of an adduct. Methods of making solvates include, but are not limited to, storage in an atmosphere containing a solvent, dosage forms that include the solvent, or routine pharmaceutical processing steps such as, for example,
- 25 crystallization (*i.e.*, from solvent or mixed solvents) vapor diffusion, *etc.* Solvates may also be formed, under certain circumstances, from other crystalline solvates or hydrates upon exposure to the solvent or upon suspension material in solvent. Solvates may crystallize in more than one form resulting in solvate polymorphism. See *e.g.*, (Guillory, K., Chapter 5, pp. 205-208 in *Polymorphism*
- 30 *in Pharmaceutical Solids*, (Brittain, H. ed.), Marcel Dekker, Inc., New York, NY, 1999)). The above methods for preparing solvates are well within the ambit of those of skill in the art, are completely conventional do not require any

experimentation beyond what is typical in the art. Solvates may be characterized and/or analyzed by methods well known to those of skill in the art such as, for example, single crystal X-ray diffraction, X-ray powder diffraction, Polarizing optical microscopy, thermal microscopy, thermogravimetry, differential thermal analysis, differential scanning calorimetry, IR spectroscopy, Raman spectroscopy and NMR spectroscopy. (Brittain, H., Chapter 6, pp. 205-208 in *Polymorphism in Pharmaceutical Solids*, (Brittain, H. ed.), Marcel Dekker, Inc. New York, 1999). In addition, many commercial companies routine offer services that include preparation and/or characterization of solvates such as, for example, HOLODIAG, Pharmaparc II, Voie de l'Innovation, 27 100 Val de Reuil, France (<http://www.holodiag.com>).

“Substituted” when used to modify a specified group or radical, means that one or more hydrogen atoms of the specified group or radical are each, independently of one another, replaced with the same or different substituent(s). Substituent groups useful for substituting saturated carbon atoms in the specified group or radical include, but are not limited to $-R^a$, halo, $-O^-$, $=O$, $-OR^b$, $-SR^b$, $-S^-$, $=S$, $-NR^cR^c$, $=NR^b$, $=N-OR^b$, trihalomethyl, $-CF_3$, $-CN$, $-OCN$, $-SCN$, $-NO$, $-NO_2$, $=N_2$, $-N_3$, $-S(O)_2R^b$, $-S(O)_2NR^b$, $-S(O)_2O^-$, $-S(O)_2OR^b$, $-OS(O)_2R^b$, $-OS(O)_2O^-$, $-OS(O)_2OR^b$, $-P(O)(O^-)_2$, $-P(O)(OR^b)(O^-)$, $-P(O)(OR^b)(OR^b)$, $-C(O)R^b$, $-C(S)R^b$, $-C(NR^b)R^b$, $-C(O)O^-$, $-C(O)OR^b$, $-C(S)OR^b$, $-C(O)NR^cR^c$, $-C(NR^b)NR^cR^c$, $-OC(O)R^b$, $-OC(S)R^b$, $-OC(O)O^-$, $-OC(O)OR^b$, $-OC(S)OR^b$, $-NR^bC(O)R^b$, $-NR^bC(S)R^b$, $-NR^bC(O)O^-$, $-NR^bC(O)OR^b$, $-NR^bC(S)OR^b$, $-NR^bC(O)NR^cR^c$, $-NR^bC(NR^b)R^b$ and $-NR^bC(NR^b)NR^cR^c$, where R^a is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl; each R^b is independently hydrogen or R^a ; and each R^c is independently R^b or alternatively, the two R^c 's are taken together with the nitrogen atom to which they are bonded form a 4-, 5-, 6- or 7-membered cycloheteroalkyl which may optionally include from 1 to 4 of the same or different additional heteroatoms selected from the group consisting of O, N and S. As specific examples, $-NR^cR^c$ is meant to include $-NH_2$, $-NH$ -alkyl, N-pyrrolidinyl and N-morpholinyl.

Similarly, substituent groups useful for substituting unsaturated carbon atoms in the specified group or radical include, but are not limited to, $-R^a$, halo, $-O^-$, $-OR^b$, $-SR^b$, $-S^-$, $-NR^cR^c$, trihalomethyl, $-CF_3$, $-CN$, $-OCN$, $-SCN$, $-NO$, $-NO_2$, $-N_3$, $-S(O)_2R^b$, $-S(O)_2O^-$, $-S(O)_2OR^b$, $-OS(O)_2R^b$, $-OS(O)_2O^-$, $-OS(O)_2OR^b$,
5 $-P(O)(O^-)_2$, $-P(O)(OR^b)(O^-)$, $-P(O)(OR^b)(OR^b)$, $-C(O)R^b$, $-C(S)R^b$, $-C(NR^b)R^b$, $-C(O)O^-$, $-C(O)OR^b$, $-C(S)OR^b$, $-C(O)NR^cR^c$, $-C(NR^b)NR^cR^c$, $-OC(O)R^b$, $-OC(S)R^b$, $-OC(O)O^-$, $-OC(O)OR^b$, $-OC(S)OR^b$, $-NR^bC(O)R^b$, $-NR^bC(S)R^b$, $-NR^bC(O)O^-$, $-NR^bC(O)OR^b$, $-NR^bC(S)OR^b$, $-NR^bC(O)NR^cR^c$, $-NR^bC(NR^b)R^b$ and $-NR^bC(NR^b)NR^cR^c$, where R^a , R^b and R^c are as previously defined.

10 Substituent groups useful for substituting nitrogen atoms in heteroalkyl and cycloheteroalkyl groups include, but are not limited to, $-R^a$, $-O^-$, $-OR^b$, $-SR^b$, $-S^-$, $-NR^cR^c$, trihalomethyl, $-CF_3$, $-CN$, $-NO$, $-NO_2$, $-S(O)_2R^b$, $-S(O)_2O^-$, $-S(O)_2OR^b$, $-OS(O)_2R^b$, $-OS(O)_2O^-$, $-OS(O)_2OR^b$, $-P(O)(O^-)_2$, $-P(O)(OR^b)(O^-)$, $-P(O)(OR^b)(OR^b)$, $-C(O)R^b$, $-C(S)R^b$, $-C(NR^b)R^b$, $-C(O)OR^b$, $-C(S)OR^b$,
15 $-C(O)NR^cR^c$, $-C(NR^b)NR^cR^c$, $-OC(O)R^b$, $-OC(S)R^b$, $-OC(O)OR^b$, $-OC(S)OR^b$, $-NR^bC(O)R^b$, $-NR^bC(S)R^b$, $-NR^bC(O)OR^b$, $-NR^bC(S)OR^b$, $-NR^bC(O)NR^cR^c$, $-NR^bC(NR^b)R^b$ and $-NR^bC(NR^b)NR^cR^c$, where R^a , R^b and R^c are as previously defined.

20 Substituent groups from the above lists useful for substituting other specified groups or atoms will be apparent to those of skill in the art. The substituents used to substitute a specified group can be further substituted, typically with one or more of the same or different groups selected from the various groups specified above. In some embodiments, substituents are limited to the groups above.

25 “Subject,” “individual” or “patient” is used interchangeably herein and refers to a vertebrate, preferably a mammal. Mammals include, but are not limited to, murines, rodents, simians, humans, farm animals, sport animals and pets.

30 “Treating” or “treatment” of any disease or disorder refers, in some embodiments, to ameliorating the disease or disorder (*i.e.*, arresting or reducing the development of the disease or at least one of the clinical symptoms thereof.).

Treatment may also be considered to include preemptive or prophylactic administration to ameliorate, arrest or prevent the development of the disease or at least one of the clinical symptoms. Treatment can also refer to the lessening of the severity and/or the duration of one or more symptoms of a disease or disorder.

5 In a further feature, the treatment rendered has lower potential for long term side effects over multiple years. In other embodiments “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the patient. In yet other embodiments, “treating” or “treatment” refers to inhibiting the disease or disorder, either physically, (*e.g.*, stabilization of


10 a discernible symptom), physiologically, (*e.g.*, stabilization of a physical parameter) or both. In yet other embodiments, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

“Therapeutically effective amount” means the amount of a compound that, when administered to a patient for treating a disease, is sufficient to effect such treatment for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, adsorption, distribution, metabolism and excretion *etc.*, of the patient to be treated.

“Vehicle” refers to a diluent, excipient or carrier with which a compound is administered to a subject. In some embodiments, the vehicle is pharmaceutically acceptable.

Compounds

Provided herein, in one aspect, are compounds of Formula (I):



(I)


or salts, hydrates or solvates thereof wherein:

- R_1 is hydrogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, $-\text{SiR}_6\text{R}_7\text{R}_8$, alkyl substituted with one or more $\text{SiR}_6\text{R}_7\text{R}_8$, $-\text{CH}=\text{NOR}_{13}$ or optionally R_1 and R_2 together with the atom to which they are connected form a 5, 6 or 7 membered cycloalkyl or cycloheteroalkyl ring or substituted cycloalkyl or cycloheteroalkyl ring;
- R_2 is hydrogen, alkyl, substituted alkyl $-\text{NO}_2$ or $-\text{NH}_2$;
- R_3 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, or $-\text{OR}_9$ or optionally R_3 and R_4 together with the atom to which they are connected form a 5, 6 or 7 membered cycloalkyl or cycloheteroalkyl ring or substituted cycloalkyl or cycloheteroalkyl ring
- R_4 is hydrogen or halogen;
- R_5 is alkyl, aryl, arylalkyl, acyl or $-(\text{L})_n\text{-P}$;
- R_6 , R_7 or R_8 are independently alkyl or arylalkyl;
- R_9 is hydrogen, alkyl, substituted alkyl, $-\text{C}(\text{O})\text{R}_{10}$ $-\text{C}(\text{O})\text{OR}_{10}$ or $-\text{C}(\text{O})\text{NR}_{11}\text{R}_{12}$, $-\text{P}$ or $-(\text{L})_n\text{-P}$;
- R_{10} is alkyl, substituted alkyl, arylalkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;
- R_{11} , R_{12} and R_{13} are independently alkyl, substituted alkyl, arylalkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl or optionally R_{12} and R_{13} together with the atom to which they are connected form a 5, 6 or 7 membered cycloheteroalkyl ring or substituted cycloheteroalkyl ring;
- L is a linker;
- P is a polymer; and
- n is 0 or 1
- provided that when R_1 , R_2 , R_3 and R_4 are hydrogen that R_5 is not $-\text{Ph}$, $-\text{C}_2\text{H}_5$, $-\text{C}_5\text{H}_{11}$, $-\text{C}_6\text{H}_{13}$, $-\text{C}_7\text{H}_{15}$, $-\text{C}_8\text{H}_{17}$, $-\text{C}_{15}\text{H}_{31}$, $-\text{C}_3\text{H}_6\text{C}\equiv\text{CH}$, $-\text{C}_3\text{H}_6\text{C}\equiv\text{CH}$, $-\text{C}_3\text{H}_6\text{C}=\text{CH}_2$ or $-\text{C}=\text{CH}(\text{CH}_3)$;
- provided that when R_1 , R_3 and R_4 are hydrogen and R_2 is $-\text{NO}_2$ that R_5 is not $-\text{Ph}$ or $-\text{C}_5\text{H}_{11}$;
- provided that when R_1 , R_3 and R_4 are hydrogen, and R_2 is $-\text{NH}_2$ that R_5 is not $-\text{Ph}$, $-\text{C}_5\text{H}_{11}$ or $-\text{C}_8\text{H}_{17}$;
- provided that when R_1 , R_2 and R_4 are hydrogen and R_3 is $-\text{OCH}_3$ that R_5 is not $-\text{C}_2\text{H}_5$ or $-\text{C}_5\text{H}_{11}$;


provided that when R_2 , R_3 and R_4 are hydrogen and R_1 is $-\text{CH}_3$ that R_5 is not $-\text{Ph}$ or $-\text{C}_6\text{H}_{13}$;

provided that when R_2 , R_3 and R_4 are hydrogen and R_1 is $-\text{CH}_2\text{OH}$ that R_5 is not $-\text{C}_5\text{H}_{11}$ or $-\text{C}_6\text{H}_{13}$;


5 provided that when R_2 , R_3 and R_4 are hydrogen and R_1



provided that when R_2 , R_3 and R_4 are hydrogen and R_1



provided that when R_2 , R_3 and R_4 are hydrogen and R_1




provided that when R_1 , R_2 and R_4 are hydrogen and R_3 is $-\text{C}(\text{O})\text{R}_{10}$ that R_5 and R_{10} are not identical;

provided that when R_2 and R_4 are hydrogen, R_1 is $-\text{C}_2\text{H}_5$ and R_3 is $-\text{C}(\text{O})\text{R}_{10}$ that R_5 and R_{10} are not identical;

15 provided that when R_2 and R_4 are hydrogen, R_1 is $-\text{C}_2\text{H}_5$ and R_3 is $-\text{H}$ that R_5 is not $\text{C}_{10}\text{H}_{21}$; and


provided that when R_2 and R_4 are hydrogen, R_1 is $-\text{C}_2\text{H}_5$ and R_3 is $-\text{C}(\text{O})\text{OtBu}$ that R_5 is not $\text{C}_{10}\text{H}_{21}$.

20 In some embodiments, a compound having the structure of Formula (II) is provided:




(II)

In other embodiments, a compound having the structure of Formula (III) is provided:




(III)

5 In still other embodiments, a compound having the structure of Formula (IV) is provided:




(IV)

10 In still other embodiments, a compound having the structure of Formula (V) is provided:



(V)


In still other embodiments, a compound having the structure of Formula (VI) is provided:



15

(VI)


In still other embodiments, a compound having the structure of Formula (VII) is provided:



5

(VII)


In still other embodiments, a compound having the structure of Formula (VIII) is provided:



(VIII)

10


In still other embodiments, a compound having the structure of Formula (IX) is provided:



(IX)


15

In still other embodiments, a compound having the structure of Formula (X) is provided:




(X)

In still other embodiments, a compound having the structure of Formula (XI) is provided:




(XI)

5 In still other embodiments, a compound having the structure of Formula (XII) is provided:




(XII)

10 In still other embodiments, a compound having the structure of Formula (XIII) is provided:



(XIII)

In still other embodiments, a compound having the structure of Formula (XIV) is provided:



(XIV)

15

In some embodiments, R₁, R₂, R₃ and R₄ are not hydrogen. In other embodiments, R₅ is alkyl or acyl. In still other embodiments, R₅ is (C₁₀-C₂₀) alkyl. In still other embodiments, R₅ is *n*-C₁₀H₂₁, *n*-C₁₁H₂₃, *n*-C₁₀H₂₁, *n*-C₁₂H₂₅, *n*-C₁₃H₂₇, *n*-C₁₄H₂₉, *n*-C₁₅H₃₁, *n*-C₁₆H₃₃, *n*-C₁₇H₃₅, *n*-C₁₈H₃₇, *n*-C₁₉H₃₉ or *n*-C₂₀H₄₁. In still other embodiments, R₅ is (C₁₀-C₂₀) acyl. In still other

5 embodiments, R₅ is -C(O)*n*-C₁₀H₂₁, -C(O)*n*-C₁₁H₂₃, -C(O)*n*-C₁₀H₂₁, -C(O)*n*-C₁₂H₂₅, -C(O)*n*-C₁₃H₂₇, -C(O)*n*-C₁₄H₂₉, -C(O)*n*-C₁₅H₃₁, -C(O)*n*-C₁₆H₃₃, -C(O)*n*-C₁₇H₃₅, -C(O)*n*-C₁₈H₃₇, -C(O)*n*-C₁₉H₃₉ or -C(O)*n*-C₁₉H₃₉.

A linker (*i.e.*, L), typically contains at least two functional groups, *e.g.*,

10 one functional group that can be used to form a bond with the hydroxyl group of camptothecin or camptothecin derivative and another functional group that can form a bond with a polymer. Typically, though not necessarily, the functional group on the linker that is used to form a bond with the camptothecin or camptothecin derivative is at one end of the linker and the functional group that is

15 used to form a bond with the polymer is at the other end of the linker.

The linker will typically comprise electrophilic functional groups that can react with the nucleophilic hydroxyl group on the camptothecin or camptothecin derivative to form a covalent bond. The linker can comprise nucleophilic functional groups that can react with electrophilic functional groups like

20 carbonyl, halide, or alkoxyl groups on the polymer. The linker can also comprise electrophilic groups that can react with nucleophilic functional groups on the polymer. Any of these bonds may be formed by conventional methods known in the art. The resulting bonds between the linker, camptothecin or camptothecin derivative and the polymer should be biodegradable.

The linker can be of varying lengths, such as from 1 to 20 atoms in length. For example, the linker moiety can be from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 atoms in length, where any of the stated values can form an upper and/or lower end point of a range. Further, the linker moiety can be substituted or unsubstituted. When substituted, the linker can contain

25 substituents attached to the backbone of the linker or substituents embedded in the backbone of the linker. For example, an amine substituted linker moiety can

30

contain an amine group attached to the backbone of the linker or a nitrogen in the backbone of the linker.

Suitable linkers include, but are not limited to alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, ethers, esters, polyethers, polyesters, polyalkylenes, polyamines and the like. In a specific example, the linker can comprise $-(CH_2)_m-$, wherein m is from 1 to 20, and where the point of attachment to the camptothecin or camptothecin derivative is an ether, ester, carbonate or carbamate bond and the point of attachment to the polymer is an ester, ether, carbamate, amine, or amide bond. For example, the linker moiety can be $X^1-(CH_2)_m-X^2$, wherein m is from 1 to 10, and X^1 is $-C(O)-$, a bond or $-C(O)N-$, $-C(O)O-$ and X^2 $-C(O)$, $-C(O)O-$, $-C(O)N-$, $-NH-$, $-O-$ or halo.

In still another embodiment, the linker can comprise a branched or straight-chain alkyl, wherein one or more of the carbon atoms is substituted with oxygen (*e.g.*, an ether) or an amino group. For example, suitable linkers can include, but are not limited to, a methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, methylaminomethyl, methylaminoethyl, methylaminopropyl, methylaminobutyl, ethylaminomethyl, ethylaminoethyl, ethylaminopropyl, propylaminomethyl, propylaminoethyl, methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, methoxymethoxyethyl, and the like, and derivatives thereof, where the point of attachment to the hydrophobic drug and/or amino acid is an ester, ether, or amide bond.

Exemplary polymers include, but are not limited to poly(D-lactide), poly(L-lactide), poly(D,L-lactide), poly(lactide-co-glycolide), polycaprolactone, poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(lactic-co-glycolic acid) (PGLA) and/or poly(1,6-bis-p-carboxyphenoxyhexane-co-sebacic anhydride). These copolymers may take the form of random, block, or alternating copolymer, depending on the monomer sequence. Other polymers of use include, but are not limited to, PHMPA, PHMPA-PLMA, PEG, dextran, chitosan and pullan.

Methods for the preparation of compounds of Formulae (I)-(XIV) are conventional and within the ambit of the skilled artisan.

Compositions and Methods of Administration

5 The compositions provided herein contain therapeutically effective amounts of one or more of the compounds provided herein that are useful in the prevention, treatment, or amelioration of one or more of the symptoms of diseases or disorders described herein and a vehicle. Vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of
10 administration.

In addition, the compounds may be formulated as the sole active ingredient in the composition or may be combined with other active ingredients.

The compositions contain one or more compounds provided herein. The compounds are, in some embodiments, formulated into suitable preparations such
15 as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration, as well as topical administration, transdermal administration and oral inhalation via nebulizers, pressurized metered dose inhalers and dry powder inhalers. In some
20 embodiments, the compounds described above are formulated into compositions using techniques and procedures well known in the art (see, *e.g.*, Ansel, Introduction to Pharmaceutical Dosage Forms, Seventh Edition (1999)).

In the compositions, effective concentrations of one or more compounds or derivatives thereof is (are) mixed with a suitable vehicle. The compounds may
25 be derivatized as the corresponding salts, esters, enol ethers or esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, ion-pairs, hydrates or prodrugs prior to formulation, as described above. The concentrations of the compounds in the compositions are effective for delivery of an amount, upon administration that treats, leads to prevention, or amelioration of
30 one or more of the symptoms of diseases or disorders described herein. In some

embodiments, the compositions are formulated for single dosage administration. To formulate a composition, the weight fraction of a compound is dissolved, suspended, dispersed or otherwise mixed in a selected vehicle at an effective concentration such that the treated condition is relieved, prevented, or one or
5 more symptoms are ameliorated.

The active compound is included in the vehicle in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be predicted empirically by testing the compounds in *in vitro* and *in vivo* systems well known
10 to those of skill in the art and then extrapolated therefrom for dosages for humans. Human doses are then typically fine-tuned in clinical trials and titrated to response.

The concentration of active compound in the composition will depend on absorption, inactivation and excretion rates of the active compound, the
15 physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art. For example, the amount that is delivered is sufficient to ameliorate one or more of the symptoms of diseases or disorders as described herein.

In some embodiments, a therapeutically effective dosage should produce a
20 serum concentration of active ingredient of from about 0.001 ng/ml to about 1.0 ng/ml, 2-10 ng/ml, 11 to 50 ng/ml, 51-200 ng/ml, or about 200 to 1000 ng/ml. The compositions, in other embodiments, should provide a dosage of from about 0.0001 mg to about 70 mg of compound per kilogram of body weight per day. Dosage unit forms are prepared to provide from about 0.01 mg, 0.1 mg or 1 mg to
25 about 500 mg, or about 1000 mg, and in some embodiments from about 10 mg to about 500 mg of the active ingredient or a combination of essential ingredients per dosage unit form.

The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is
30 understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing

protocols or by extrapolation from *in vivo* or *in vitro* test data or subsequent clinical testing. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be
5 adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

10 In instances in which the compounds exhibit insufficient solubility, methods for solubilizing compounds may be used such as use of liposomes, prodrugs, complexation/chelation, nanoparticles, or emulsions or tertiary templating. Such methods are known to those of skill in this art, and include, but are not limited to, using co-solvents, such as dimethylsulfoxide (DMSO), using
15 surfactants or surface modifiers, such as TWEEN[®], complexing agents such as cyclodextrin or dissolution by enhanced ionization (i.e. dissolving in aqueous sodium bicarbonate). Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective compositions.

20 Upon mixing or addition of the compound(s), the resulting mixture may be a solution, suspension, emulsion or the like. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease, disorder or condition treated and may be empirically determined.

25 The compositions are provided for administration to humans and animals in indication appropriate dosage forms, such as dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs), nebulizers, tablets, capsules, pills, sublingual tapes/bioerodible strips, tablets or capsules, powders, granules, lozenges, lotions, salves, suppositories, fast melts, transdermal patches or other
30 transdermal application devices/preparations, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions

containing suitable quantities of the compounds or derivatives thereof. The therapeutically active compounds and derivatives thereof are, in some embodiments, formulated and administered in unit-dosage forms or multiple-dosage forms. Unit-dose forms as used herein refer to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required vehicle. Examples of unit-dose forms include ampoules and syringes and individually packaged tablets or capsules.

Unit-dose forms may be administered in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit-doses which are not segregated in packaging.

Liquid compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional adjuvants in a vehicle, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension, colloidal dispersion, emulsion or liposomal formulation. If desired, the composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.

Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975 or later editions thereof.

Dosage forms or compositions containing active ingredient in the range of 0.005% to 100% with the balance made up from vehicle or carrier may be

prepared. Methods for preparation of these compositions are known to those skilled in the art. The contemplated compositions may contain 0.001%-100% active ingredient, in one embodiment 0.1-95%, in another embodiment 0.4-10%.

5 In certain embodiments, the compositions are lactose-free compositions containing excipients that are well known in the art and are listed, for example, in the *U.S. Pharmacopeia* (USP) 25-NF20 (2002). In general, lactose-free compositions contain active ingredients, a binder/filler, and a lubricant in compatible amounts. Particular lactose-free dosage forms contain active ingredients, microcrystalline cellulose, pre-gelatinized starch, and magnesium
10 stearate.

Further provided are anhydrous compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds. For example, the addition of water (*e.g.*, 5%) is widely accepted as a means of simulating long-term storage in order to determine characteristics such
15 as shelf-life or the stability of formulations over time. *See, e.g.*, Jens T. Carstensen, *Drug Stability: Principles & Practice*, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80. In effect, water and heat accelerate the decomposition of some compounds. Thus, the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during
20 manufacture, handling, packaging, storage, shipment, and use of formulations.

Anhydrous compositions and dosage forms provided herein can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.

25 An anhydrous composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are generally packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (*e.g.*, vials), blister packs, and strip packs.

Oral dosage forms are either solid, gel or liquid. The solid dosage forms are tablets, capsules, granules, and bulk powders. Types of oral tablets include compressed, chewable lozenges and tablets which may be enteric-coated, sugar-coated or film-coated. Capsules may be hard or soft gelatin capsules, while
5 granules and powders may be provided in non-effervescent or effervescent form with the combination of other ingredients known to those skilled in the art.

In certain embodiments, the formulations are solid dosage forms such as for example, capsules or tablets. The tablets, pills, capsules, troches and the like can contain one or more of the following ingredients, or compounds of a similar
10 nature: a binder; a lubricant; a diluent; a glidant; a disintegrating agent; a coloring agent; a sweetening agent; a flavoring agent; a wetting agent; an enteric coating; a film coating agent and modified release agent. Examples of binders include microcrystalline cellulose, methyl paraben, polyalkyleneoxides, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, molasses,
15 polyvinylpyrrolidone, povidone, crospovidones, sucrose and starch and starch derivatives. Lubricants include talc, starch, magnesium/calcium stearate, lycopodium and stearic acid. Diluents include, for example, lactose, sucrose, trehalose, lysine, leucine, lecithin, starch, kaolin, salt, mannitol and dicalcium phosphate. Glidants include, but are not limited to, colloidal silicon dioxide.
20 Disintegrating agents include crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. Coloring agents include, for example, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate and advanced coloring or
25 anti-forgery color/opalescent additives known to those skilled in the art. Sweetening agents include sucrose, lactose, mannitol and artificial sweetening agents such as saccharin, and any number of spray dried flavors. Flavoring agents include natural flavors extracted from plants such as fruits and synthetic blends of compounds which produce a pleasant sensation or mask unpleasant
30 taste, such as, but not limited to peppermint and methyl salicylate. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether. Enteric-coatings include

fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates. Film coatings include hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate. Modified release agents include polymers such as the Eudragit® series
5 and cellulose esters.

The compound, or derivative thereof, can be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition
10 may also be formulated in combination with an antacid or other such ingredient.

When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents. The
15 compounds can also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

The active materials can also be mixed with other active materials which
20 do not impair the desired action, or with materials that supplement the desired action, such as antacids, H₂ blockers, and diuretics. The active ingredient is a compound or derivative thereof as described herein. Higher concentrations, up to about 98% by weight of the active ingredient may be included.

In all embodiments, tablets and capsules formulations may be coated as
25 known by those of skill in the art in order to modify or sustain dissolution of the active ingredient. Thus, for example, they may be coated with a conventional enterically digestible coating, such as phenylsalicylate, waxes and cellulose acetate phthalate.

Liquid oral dosage forms include aqueous solutions, emulsions,
30 suspensions, solutions and/or suspensions reconstituted from non-effervescent

granules and effervescent preparations reconstituted from effervescent granules. Aqueous solutions include, for example, elixirs and syrups. Emulsions are either oil-in-water or water-in-oil.

5 Elixirs are clear, sweetened, hydroalcoholic preparations. Vehicles used in elixirs include solvents. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may contain a preservative. An emulsion is a two-phase system in which one liquid is dispersed in the form of small globules throughout another liquid. Carriers used in emulsions are non-aqueous liquids, emulsifying agents and preservatives. Suspensions use suspending agents and
10 preservatives. Acceptable substances used in non-effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents. Acceptable substances used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic acids and a source of carbon dioxide. Coloring and flavoring agents are used in all of the above dosage
15 forms.

Solvents include glycerin, sorbitol, ethyl alcohol and syrup. Examples of preservatives include glycerin, methyl and propylparaben, benzoic acid, sodium benzoate and alcohol. Examples of non-aqueous liquids utilized in emulsions include mineral oil and cottonseed oil. Examples of emulsifying agents include
20 gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate. Suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia. Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as saccharin. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene
25 glycol monolaurate and polyoxyethylene lauryl ether. Organic acids include citric and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate. Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof. Flavoring agents include
30 natural flavors extracted from plants such fruits, and synthetic blends of compounds which produce a pleasant taste sensation.

For a solid dosage form, the solution or suspension, in for example, propylene carbonate, vegetable oils or triglycerides, is in some embodiments encapsulated in a gelatin capsule. Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Patent Nos. 4,328,245; 4,409,239;
5 and 4,410,545. For a liquid dosage form, the solution, *e.g.*, for example, in a polyethylene glycol, may be diluted with a sufficient quantity of a liquid vehicle, *e.g.*, water, to be easily measured for administration.

Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols,
10 triglycerides, propylene glycol esters (*e.g.*, propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include those set forth in U.S. Patent Nos. RE 28,819 and 4,358,603. Briefly, such formulations include, but are not limited to, those containing a compound provided herein, a dialkylated mono- or
15 polyalkylene glycol, including, but not limited to, 1,2-dimethoxyethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether wherein 350, 550 and 750 refer to the approximate average molecular weight of the polyethylene glycol, and one or more antioxidants, such as butylated
20 hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamates.

Other formulations include, but are not limited to, aqueous alcoholic
25 solutions including an acetal. Alcohols used in these formulations are any water-miscible solvents having one or more hydroxyl groups, including, but not limited to, propylene glycol and ethanol. Acetals include, but are not limited to, di(lower alkyl) acetals of lower alkyl aldehydes such as acetaldehyde diethyl acetal.

30 Parenteral administration, in some embodiments characterized by injection, either subcutaneously, intramuscularly or intravenously is also

contemplated herein. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. The injectables, solutions and emulsions also contain one or more excipients. Suitable excipients are, for example, water, saline, dextrose, glycerol or ethanol. In addition, if desired, the compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.

10 Implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained (see, *e.g.*, U.S. Patent No. 3,710,795) is also contemplated herein. Briefly, a compound provided herein is dispersed in a solid inner matrix, *e.g.*, polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized
15 polyethyleneterephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinylacetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinylalcohol and cross-linked partially hydrolyzed polyvinyl acetate, that is
20 surrounded by an outer polymeric membrane, *e.g.*, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinylacetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinylchloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene,
25 ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer, that is insoluble in body fluids. The compound diffuses through the outer polymeric membrane in a release rate controlling step. The percentage of active compound contained in
30 such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.

Parenteral administration of the compositions includes intravenous, subcutaneous and intramuscular administrations. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous.

If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.

Vehicles used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other substances.

Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations must be added to parenteral preparations packaged in multiple-dose containers which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include Polysorbate 80 (Tween® 80). A sequestering or chelating agent of metal ions includes EDTA. Carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water

miscible vehicles; and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.

The concentration of compound is adjusted so that an injection provides an effective amount to produce the desired pharmacological effect. The exact
5 dose depends on the age, weight, body surface area and condition of the patient or animal as is known in the art.

The unit-dose parenteral preparations are packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration must be sterile, as is known and practiced in the art.

10 Illustratively, intravenous or intraarterial infusion of a sterile aqueous solution containing an active compound is an effective mode of administration. Another embodiment is a sterile aqueous or oily solution or suspension containing an active material injected as necessary to produce the desired pharmacological effect.

15 Injectables are designed for local and systemic administration. In some embodiments, a therapeutically effective dosage is formulated to contain a concentration of at least about 0.01% w/w up to about 90% w/w or more, in certain embodiments more than 0.1% w/w of the active compound to the treated tissue(s).

20 The compound may be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for
25 ameliorating the symptoms of the condition and may be empirically determined.

Active ingredients provided herein can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533;
30 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480;

5,733,566; 5,739,108; 5,891,474; 5,922,356; 5,972,891; 5,980,945; 5,993,855; 6,045,830; 6,087,324; 6,113,943; 6,197,350; 6,248,363; 6,264,970; 6,267,981; 6,376,461; 6,419,961; 6,589,548; 6,613,358; 6,699,500 and 6,740,634. Such dosage forms can be used to provide slow or controlled-release of one or more
5 active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled-release formulations known to those of ordinary skill in the art,
10 including those described herein, can be readily selected for use with the active ingredients provided herein.

All controlled-release products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is
15 characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as
20 blood levels of the drug, and can thus affect the occurrence of side (*e.g.*, adverse) effects.

Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain
25 this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to,
30 pH, temperature, enzymes, water, or other physiological conditions or compounds.

In certain embodiments, the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In some embodiments, a pump may be used (*see*, Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald *et al.*, *Surgery* 5 88:507 (1980); Saudek *et al.*, *N. Engl. J. Med.* 321:574 (1989)). In other embodiments, polymeric materials can be used. In other embodiments, a controlled release system can be placed in proximity of the therapeutic target, *i.e.*, thus requiring only a fraction of the systemic dose (*see, e.g.*, Goodson, *Medical Applications of Controlled Release*, vol. 2, pp. 115-138 (1984)). In some 10 embodiments, a controlled release device is introduced into a subject in proximity of the site of inappropriate immune activation or a tumor. Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)). The active ingredient can be dispersed in a solid inner matrix, *e.g.*, polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized 15 polyvinylchloride, plasticized nylon, plasticized polyethyleneterephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinylacetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinylalcohol and 20 cross-linked partially hydrolyzed polyvinyl acetate, that is surrounded by an outer polymeric membrane, *e.g.*, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinylacetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinylchloride copolymers with vinyl 25 acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer, that is insoluble in body fluids. The active ingredient then diffuses through the outer polymeric membrane in a release rate 30 controlling step. The percentage of active ingredient contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the needs of the subject.

Of interest, herein are also lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. They may also be reconstituted and formulated as solids or gels.

5 The sterile, lyophilized powder is prepared by dissolving a compound provided herein, or a derivative thereof, in a suitable solvent. The solvent may contain an excipient which improves the stability or other pharmacological component of the powder or reconstituted solution, prepared from the powder. Excipients that may be used include, but are not limited to, an antioxidant, a buffer and a bulking agent. In some embodiments, the excipient is selected from
10 dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose and other suitable agents. The solvent may contain a buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, at about neutral pH. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art
15 provides the desired formulation. In some embodiments, the resulting solution will be apportioned into vials for lyophilization. Each vial will contain a single dosage or multiple dosages of the compound. The lyophilized powder can be stored under appropriate conditions, such as at about 4 °C to room temperature.

Reconstitution of this lyophilized powder with water for injection
20 provides a formulation for use in parenteral administration. For reconstitution, the lyophilized powder is added to sterile water or other suitable carriers. The precise amount depends upon the selected compound. Such amount can be empirically determined.

Topical mixtures are prepared as described for the local and systemic
25 administration. The resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.

30 The compounds or derivatives thereof may be formulated as aerosols for topical application, such as by inhalation (see, *e.g.*, U.S. Patent Nos. 4,044,126,

4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment of inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in
5 combination with an inert carrier such as lactose. In such a case, the particles of the formulation will, in some embodiments, have mass median geometric diameters of less than 5 microns, in other embodiments less than 10 microns.

Oral inhalation formulations of the compounds or derivatives suitable for inhalation include metered dose inhalers, dry powder inhalers and liquid
10 preparations for administration from a nebulizer or metered dose liquid dispensing system. For both metered dose inhalers and dry powder inhalers, a crystalline form of the compounds or derivatives is the preferred physical form of the drug to confer longer product stability.

In addition to particle size reduction methods known to those skilled in
15 the art, crystalline particles of the compounds or derivatives can be generated using supercritical fluid processing which offers significant advantages in the production of such particles for inhalation delivery by producing respirable particles of the desired size in a single step. (*e.g.*, International Publication No. WO2005/025506). A controlled particle size for the microcrystals can be
20 selected to ensure that a significant fraction of the compounds or derivatives is deposited in the lung. In some embodiments, these particles have a mass median aerodynamic diameter of about 0.1 to about 10 microns, in other embodiments, about 1 to about 5 microns and still other embodiments, about 1.2 to about 3 microns.

25 Inert and non-flammable HFA propellants are selected from HFA 134a (1,1,1,2-tetrafluoroethane) and HFA 227e (1,1,1,2,3,3,3-heptafluoropropane) and provided either alone or as a ratio to match the density of crystal particles of the compounds or derivatives. A ratio is also selected to ensure that the product suspension avoids detrimental sedimentation or cream (which can precipitate
30 irreversible agglomeration) and instead promote a loosely flocculated system, which is easily dispersed when shaken. Loosely fluctuated systems are well

regarded to provide optimal stability for pMDI canisters. As a result of the formulation's properties, the formulation contained no ethanol and no surfactants/stabilizing agents.

5 The compounds may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the active compound alone or in
10 combination with other excipients can also be administered.

For nasal administration, the preparation may contain an esterified phosphonate compound dissolved or suspended in a liquid carrier, in particular, an aqueous carrier, for aerosol application. The carrier may contain solubilizing or suspending agents such as propylene glycol, surfactants, absorption enhancers
15 such as lecithin or cyclodextrin, or preservatives.

Solutions, particularly those intended for ophthalmic use, may be formulated as 0.01% - 10% isotonic solutions, pH about 5-7.4, with appropriate salts.

20 Other routes of administration, such as transdermal patches, including iontophoretic and electrophoretic devices, and rectal administration, are also contemplated herein.

Transdermal patches, including iontophoretic and electrophoretic devices, are well known to those of skill in the art. For example, such patches are disclosed in U.S. Patent Nos. 6,267,983, 6,261,595, 6,256,533, 6,167,301,
25 6,024,975, 6,010,715, 5,985,317, 5,983,134, 5,948,433 and 5,860,957.

For example, dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories are used herein mean solid bodies for insertion into the rectum which melt or soften at body temperature releasing one or more pharmacologically or therapeutically
30 active ingredients. Substances utilized in rectal suppositories are bases or

vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used. Agents to raise the melting point of

5 suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The weight of a rectal suppository, in one embodiment, is about 2 to 3 gm. Tablets and capsules for rectal administration are manufactured using the same substance and by the same methods as for formulations for oral administration.

10 The compounds provided herein, or derivatives thereof, may also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated. Many such targeting methods are well known to those of skill in the art. All such targeting methods are contemplated herein for use in the instant compositions. For non-limiting examples of targeting methods,

15 see, *e.g.*, U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542 and 5,709,874.

In some embodiments, liposomal suspensions, including tissue-targeted liposomes, such as tumor-targeted liposomes, may also be suitable as carriers.

20 These may be prepared according to methods known to those skilled in the art. For example, liposome formulations may be prepared as described in U.S. Patent No. 4,522,811. Briefly, liposomes such as multilamellar vesicles (MLV's) may be formed by drying down phosphatidyl choline and phosphatidyl serine (7:3 molar ratio) on the inside of a flask. A solution of a compound provided herein in

25 phosphate buffered saline lacking divalent cations (PBS) is added and the flask shaken until the lipid film is dispersed. The resulting vesicles are washed to remove unencapsulated compound, pelleted by centrifugation, and then resuspended in PBS.

The compounds described herein may be formulated in compositions

30 described in the art for delivery of hydrophobic medicines (see, *e.g.*, United States Patent Nos. 5,645,856, 6,096,338, 5,510,103, 5,955,509, 6,322,817,

6,555,139, 6,579,519, 6,746,653, 6,834,791, 7,094,810, 8,715,741 and 8,414,926) or a s composite nanoparticles described in United States Provisional Patent No. 62/305,526.

5 The compounds or derivatives may be packaged as articles of manufacture containing packaging material, a compound or derivative thereof provided herein, which is effective for treatment, prevention or amelioration of one or more symptoms of the diseases or disorders, *supra*, within the packaging material, and a label that indicates that the compound or composition or derivative thereof, is used for the treatment, prevention or amelioration of one or
10 more symptoms of the diseases or disorders, *supra*.

The articles of manufacture provided herein contain packaging materials. Packaging materials for use in packaging products are well known to those of skill in the art. See, *e.g.*, U.S. Patent Nos. 5,323,907, 5,052,558 and 5,033,252. Examples of packaging materials include, but are not limited to, blister packs,
15 bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment. A wide array of formulations of the compounds and compositions provided herein are contemplated as are a variety of treatments for any disease or disorder described herein.

20 Dosages

In human therapeutics, the physician will determine the dosage regimen that is most appropriate according to a preventive or curative treatment and according to the age, weight, stage of the disease and other factors specific to the subject to be treated. The compositions, in other embodiments, should provide a
25 dosage of from about 0.0001 mg to about 70 mg of compound per kilogram of body weight per day. Dosage unit forms are prepared to provide from about 0.01 mg, 0.1 mg or 1 mg to about 500 mg, or about 1000 mg, and in some embodiments from about 10 mg to about 500 mg of the active ingredient or a combination of essential ingredients per dosage unit form.

The amount of active ingredient in the formulations provided herein, which will be effective in the prevention or treatment of a disorder or one or more symptoms thereof, will vary with the nature and severity of the disease or condition, and the route by which the active ingredient is administered. The
5 frequency and dosage will also vary according to factors specific for each subject depending on the specific therapy (*e.g.*, therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the subject.

10 Exemplary doses of a formulation include milligram or microgram amounts of the active compound per kilogram of subject (*e.g.*, from about 1 micrograms per kilogram to about 50 milligrams per kilogram, from about 10 micrograms per kilogram to about 30 milligrams per kilogram, from about 100 micrograms per kilogram to about 10 milligrams per kilogram, or from about 100
15 microgram per kilogram to about 5 milligrams per kilogram).

It may be necessary to use dosages of the active ingredient outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction
20 with subject response.

Different therapeutically effective amounts may be applicable for different diseases and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to prevent, manage, treat or ameliorate such disorders, but insufficient to cause, or sufficient to reduce,
25 adverse effects associated with the composition provided herein are also encompassed by the above described dosage amounts and dose frequency schedules. Further, when a subject is administered multiple dosages of a composition provided herein, not all of the dosages need be the same. For
30 example, the dosage administered to the subject may be increased to improve the prophylactic or therapeutic effect of the composition or it may be decreased to reduce one or more side effects that a particular subject is experiencing.

In certain embodiments, administration of the same formulation provided herein may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.

5 Methods of Use of the Compounds and Compositions

Methods of treating, preventing, or ameliorating one or more symptoms of diseases including, for example, cancer and infection also provided herein.

The compounds described herein may be used to treat or prevent cancers and/or tumors of the anus, bile duct, bladder, bone, bone marrow, bowel (including
10 colon and rectum), breast, eye, gall bladder, kidney, mouth, larynx, esophagus, stomach, testis, cervix, head, neck, ovary, lung, mesothelioma, neuroendocrine, penis, skin, spinal cord, thyroid, vagina, vulva, uterus, liver, muscle, pancreas, prostate, blood cells (including lymphocytes and other immune system cells), and brain. Specific cancers contemplated for treatment include carcinomas, Kaposi's
15 sarcoma, melanoma, mesothelioma, soft tissue sarcoma, pancreatic cancer, lung cancer, leukemia (acute lymphoblastic, acute myeloid, chronic lymphocytic, chronic myeloid, and other), and lymphoma (Hodgkin's and non-Hodgkin's), and multiple myeloma.

Other examples of cancers that can be treated according to the methods
20 disclosed herein are adrenocortical carcinoma, adenocarcinoma, cerebellar astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumor, breast cancer, Burkitt's lymphoma, carcinoid tumor, central nervous system lymphoma, cervical cancer, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, endometrial cancer,
25 ependymoma, esophageal cancer, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, hypothalamic and visual pathway glioma, intraocular melanoma, retinoblastoma, islet cell carcinoma (endocrine pancreas), laryngeal cancer, lip and oral cavity
30 cancer, liver cancer, medulloblastoma, Merkel cell carcinoma, squamous neck cancer with occult mycosis fungoides, myelodysplastic syndromes, myelogenous

leukemia, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pheochromocytoma, pineoblastoma
5 and supratentorial primitive neuroectodermal tumor, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Ewing's sarcoma, soft tissue sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, supratentorial primitive
10 neuroectodermal tumors, testicular cancer, thymic carcinoma, thymoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, trophoblastic tumor, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, Waldenström's macroglobulinemia, and Wilms' tumor.

In practicing the methods, therapeutically effective amounts of the
15 compounds or compositions, described herein, *supra*, are administered.

Combination Therapy

The compounds and compositions disclosed herein may also be used in combination with one or more other active ingredients. In certain embodiments, the compounds may be administered in combination, or sequentially, with
20 another therapeutic agent. Such other therapeutic agents include those known for treatment, prevention, or amelioration of one or more symptoms associated with, for example cancer.

It should be understood that any suitable combination of the compounds and compositions provided herein with one or more of the above therapeutic
25 agents and optionally one or more further pharmacologically active substances are considered to be within the scope of the present disclosure. In some embodiments, the compounds and compositions provided herein are administered prior to or subsequent to the one or more additional active ingredients.

Finally, it should be noted that there are alternative ways of implementing
30 the present invention. Accordingly, the present embodiments are to be considered


as illustrative and not restrictive, and the invention is not to be limited to the details given herein, but may be modified within the scope and equivalents of the appended claims.

5 All publications and patents cited herein are incorporated by reference in their entirety.

The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLES


EXAMPLE 1: Preparation of Compound 1



10


To a solution of SN38 (1 g, 2.55 mmol, 1.0 eq.) in dichloromethane (400 mL) were added pyridine (5 mL) and Boc anhydride (6.39 g, 6.371 mmol, 2.5 eq.) and the reaction mixture was stirred at room temperature for 36 h. The reaction mixture was filtered and washed with 0.01N HCl (3X). The organic phase was separated, dried (sodium sulfate) and evaporated under reduced pressure to provide compound **1** (1.26 g), which was used in the next step without further purification.

15

EXAMPLE 2: Preparation of Compound 2

To a solution of compound **1** (630 mg, 1.3 mmol, 1.0 eq) in dichloromethane (20 mL) were added N,N'-dicyclohexylcarbodiimide (DCC) (538 mg, 2.60 mmol, 2.0 eq), DMAP (190 mg, 1.56 mmol, 1.2 eq) and valeric acid (265 mg, 2.6 mmol 2.0 eq) and the reaction mixture was stirred at room temperature for 24 h.

The mixture was then filtered, dried (MgSO₄) and solvent was evaporated to provide a residue, which was purified by column chromatography to yield the valerate ester of compound **1**. The ester was then treated with 80% TFA in DCM and stirred at room temperature for 3 h. TFA was removed and the crude was purified by column chromatography to provide compound **2**(LGP001).


EXAMPLE 3: Preparation of Compound 3

To a solution of compound **1** (630 mg, 1.3 mmol, 1.0 eq) in dichloromethane (20 mL) were added N,N'-dicyclohexylcarbodiimide (DCC)

(538 mg, 2.60 mmol, 2.0 eq), DMAP (190 mg, 1.56 mmol, 1.2 eq) and tridecanoic acid (556 mg, 2.6 mmol 2.0 eq) and the reaction mix was stirred at room temperature for 24 h.

5 The mixture was then filtered, dried (MgSO₄) and solvent was evaporated to provide a residue, which was purified by column chromatography to yield BOC-SN38 ester. The ester was then treated with 80% TFA in DCM and stirred at room temperature for 3 h. TFA was removed and the crude was purified by column chromatography to provide compound **3** (LGP002).

EXAMPLE 4: Preparation of Compound 4



10

4

To a solution of PLGA-NHS (100 mg, 0.0066 mmol, 1.0 eq, Akina, Inc., 3495, Kent Ave. West Lafayette, IN 47906, cat.# A1096, approximate molecular weight of 15000) in DMF (4 mL) was added hydroxyl compound **2** (4.71 mg, 0.0099 mmol, 1.5 eq.) and DIEA (0.1 mL). The reaction mixture was stirred at room temperature for 12 h, diluted with ether to precipitate the polymer, placed in the freezer overnight and the solvents were decanted to provide a yellow viscous material. The yellow material was washed with ether (2x) and the flask was placed under vacuum to provide a yellow foamy material.

15

EXAMPLE 5: Anti-Proliferative Activity of Compounds **2** and **3**

20 Against Various Cell Lines

Human colorectal adenocarcinoma cell lines HT29 and SW620, as well as murine colon carcinoma cell line CT26, were purchased from the American Type

Culture Collection (ATCC) and grown in either Dulbecco's Modified Eagle Medium (DMEM) or Roswell Park Memorial Institute (RPMI) medium from Corning and Life Technologies, respectively. These media were supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals), as well as 1 mM sodium pyruvate (Corning) and 10 mM HEPES (Fisher) for CT26 cells. Cells were grown in Corning 75 cm² flasks and split approximately 6 days before plating, with a refeed of fresh media the day prior to plating. Anti-proliferative drugs **2**, **3** and SN38, were reconstituted in DMSO for storage at -20° C until use. AlamarBlue, a colorimetric cell metabolism reagent, was purchased from Life Technologies.

To qualify AlamarBlue incubation time and required cell density, cells were plated into flat bottom 96 well plates (Techno Plastic Products, Trasadingen, Switzerland) at plating densities from 4×10^4 to 1.25×10^3 cells per well. The cells were incubated at 37° C inside a Nu-Aire TS Autoflow incubator with 5% CO₂ and humidity for 48-72 hours, AlamarBlue reagent was then added to all wells, equivalent to 10% of the culture volume or 20 µL. The plates were returned to the 37° C incubator, and the absorbance at 570 and 600 nm were assessed using a Bio-Tek Epoch microplate reader at 1, 2, 4, 7 and in some experiment 24 hours post addition of AlamarBlue. Once the optimum cell density and incubation time was determined for each cell line, testing of the anti-proliferative drugs on the cells was initiated. For each cell line, cells were plated at 5×10^3 cells per well and incubated at 37°C for 24 hours, at which time the anti-proliferative compounds were added. Preliminary studies showed an optimum dose response of inhibition with **2** and **2** using doses from 100 µM to 0.4 µM. Aliquots of anti-proliferatives were thawed, diluted in media appropriate for each cell line, and serially diluted 1:3. A serial pipetter, was used to deliver 100 µl of each concentration of anti-proliferative compound to the appropriate wells in triplicate, the plate was tapped gently to mix, and then incubated at 37° C for 48-72 hours. Control wells containing media alone and media with an equal percentage of DMSO in comparison to the initial anti-proliferative dilution were also established in each plate. After a minimum of 48 hours of incubation, 20 µl of AlamarBlue was added to each experimental well as well as the negative

control wells. AlamarBlue positive control wells, containing 200 μ l of 100% reduced AlamarBlue, were also established to provide a colorimetric endpoint reference for the assay. After addition of AlamarBlue, plates were incubated for 4 hours at 37° C and absorbance assessed using the Epoch microplate reader.

- 5 Absorbances were used to calculate the % inhibition for each well using the following equation, where O1 is the molar extinction coefficient of oxidized AlamarBlue at 570 nm (80586), O2 is the molar extinction coefficient of oxidized AlamarBlue at 600 nm (117216), A1 is the absorbance of the test wells at 570 nm, A2 is the absorbance of the test wells at 600 nm, P1 is the absorbance of the control wells with AlamarBlue but without test agent at 570, and P2 is the absorbance of the control wells with AlamarBlue but without the test agent at 600.

$$\begin{aligned} \text{\% difference between} &= (\text{O2} \times \text{A1}) - (\text{O1} \times \text{A2}) \times 100 \\ \text{treated and untreated cells} &= (\text{O2} \times \text{P1}) - (\text{O1} \times \text{P2}) \end{aligned}$$

- 15 The dose response data generated by these values was used to calculate the half maximal inhibitory concentration (IC50) using a regression curve (3 or 4 parameter logistic sigmoidal curve or sigmoidal sigmoid curve) in Sigma Plot, version 12.5. Statistical differences were calculated using SPSS Statistics software, version 17.0, using the independent t-test with an α of 0.05.

- 20 Prior to initiation of the studies using the anti-proliferative drugs, the cell density for the assay and AlamarBlue incubation time was qualified. A range of cell concentrations was tested with repeated absorbance readings at established time points, then the resulting graphs were used to determine the optimum cell plating density. As seen in Fig. 1 and Fig. 2, the cell density controlled the optimal incubation time, with denser cells requiring less time to reach maximum reduction of AlamarBlue.

- 25 After examination of the curves generated by the experimental data shown in Fig. 1 and Fig. 2, we selected 5×10^3 as the plating density. This concentration performed well at every time point and fit within the linear portion of the curve.

30

For the incubation time, we identified the time between 2 and 7 hours to be ideal for the predetermined cell concentration, as the values from those incubation times fall within a linear curve and appeared less noisy than the longer incubations. During experiments with the anti-proliferative drugs, the plates were read at 2, 4 and 7 hours post addition of AlamarBlue, in order to have the opportunity to capture the best quality data. The 4-hour time point generally provided the data with the more complete calorimetric development with lower variance.

In the human colorectal adenocarcinoma cell line HT29, there were distinctly different dose responses for the two novel anti-proliferative drugs in comparison to SN38 as shown in Fig. 3. SN38 showed a high level of inhibition in this cell line throughout all concentrations tested, while compounds **2** (LGP001) and **3** (LGP002) had a gradual tapering of proliferative inhibition that paralleled the decrease in concentration. The dose response curve was steeper in cells treated with compound **3** (LGP002) in comparison to compound **2** (LGP001), showing lower % inhibition as the concentration of anti-proliferative decreased. At the highest concentration tested, 100 μ M, compounds **2** (LGP001) and **3** (LGP002) were not significantly different from SN38 ($p=0.984$ and $p=0.928$, respectively). However, as the concentration of anti-proliferative compound decreased, the differences in % inhibition versus SN38 were significant. At 33.3 μ M, both compounds **2** (LGP001) and **3** (LGP002) showed high inhibition, above 54%, which was significantly different from SN38 for both compounds **2** (LGP001) ($p=0.030$) and **3** (LGP002) ($p=0.003$).

	IC50
2 (LGP001)	5.6
3 (LGP002)	17.1
SN38	0.2

Table 1: IC50 of anti-proliferative drugs in HT29 cells. IC50 was calculated using a 4 parameter sigmoidal logistic regression curve for compounds **2** (LGP001) and **3** (LGP002), and a 3 parameter sigmoidal logistic regression curve for SN38.

The IC₅₀ for all three anti-proliferative drugs in HT29 cells was calculated and shown in Table 1. In agreement with the inhibitory response seen at even the lowest tested dose, the IC₅₀ of SN38 was the lowest of the three compounds, followed by **2** (LGP001) at 5.6 and finally **3** (LGP002) at 17.1.

5 In the human colorectal adenocarcinoma cell line SW620, there were again distinctly different dose responses for the two novel anti-proliferative drugs in comparison to SN38 as shown in Fig. 4. SN38 had a high level of inhibition in this cell line throughout all concentrations tested, over 55%, while compounds **2** (LGP001) and **3** (LGP002) had a gradual tapering of proliferative inhibition

10 paralleling the decrease in concentration. The decrease in inhibitory effect was more pronounced in cells treated with compound **3** (LGP002) as compared to compounds **2** (LGP001). These cells also appeared to be less sensitive to the anti-proliferative compounds than the other human cell line studied i.e., HT29, which had a lower % inhibition for compounds **2** (LGP001), **3** (LGP002) and

15 SN38 at the lowest concentration, although it was only statistically significant for SN38 ($p=0.025$). In the SW620 cells, both compounds **2** (LGP001) and **3** (LGP002) were significantly different from SN38 in activity for all concentrations tested, except for compound **2** (LGP001) at 33 μ M ($p=0.0369$).

	IC ₅₀
2 (LGP001)	1.9
3 (LGP002)	10.3
SN38	0.7

Table 2: IC₅₀ of anti-proliferative drugs in SW620 cells. IC₅₀ was calculated with a 4 parameter sigmoidal logistic regression curve for compounds **2** (LGP001) and SN38, and a 4 parameter sigmoidal sigmoid regression curve for compounds **2** (LGP001) and **3** (LGP002).

30 The IC₅₀ for all three anti-proliferative drugs in SW620 cells was calculated and shown in Table 2. Correlating to the inhibitory response seen at

even the lowest tested dose, the IC₅₀ of SN38 was the lowest of the three compounds, followed by **2** (LGP001) at 1.9 and finally **3** (LGP002) at 10.3.

In the murine colorectal carcinoma cell line CT26, there were again distinctly different dose responses for the two novel anti-proliferative drugs in comparison to SN38 as shown in Fig.5. SN38 had the higher level of inhibition for this cell line throughout all concentrations tested, although this was generally lower than what was observed in the human colorectal cancer cell lines. Compounds **2** (LGP001) and **3** (LGP002) had a gradual tapering of proliferative inhibition paralleling the decrease in concentration. The decrease in inhibitory effect was more pronounced in cells treated with compound **3** (LGP002) than compound **2** (LGP001). These cells also appeared to be less sensitive to the anti-proliferative compounds than the human cell lines, having a lower % inhibition for compound **2** (LGP001) versus SW620 cells (p=0.000) and HT29 cells (p=0.002) at the lowest concentration tested. This was also observed with CT26 cells treated with compounds **3** (LGP002), which had a lower % inhibition than SW620 cells (p=0.002) and HT29 cells (p=0.05) at the lowest concentration tested. Similar to the results seen between the two human colorectal cancer cell lines, CT26 also had a significantly lower % inhibition when treated with SN38 versus SW620 cells (p=0.000) and HT29 cells (p=0.024) at the lowest concentration. Both compounds **2** (LGP001) and **3** (LGP002) were significantly different from SN38 in activity for all concentrations tested.


The IC₅₀ for all three anti-proliferative drugs in CT26 cells was calculated and shown in Table 3. In contrast to the results seen in the other two cell lines, compound **3** (LGP002) had the lower IC₅₀ (14.2) compared to compound **2** (LGP001) (18.0) in the CT26 cells. SN38 continued to have the lowest IC₅₀ of the three compounds, at 0.6. SN38 continued to have a consistently low IC₅₀ with the murine cell line that was comparable to the IC₅₀ seen in the two human cell lines (0.6 for CT26 versus 0.7 in the SW620 cells and 0.2 in the HT29 cells). Thus, in these three cell lines, SN38 provided a consistent control value for inhibitory capability of anti-proliferative compound.

	IC50
2 (LGP001)	18.0
3 (LGP002)	14.2
SN38	0.6

Table 3: IC50 of anti-proliferative drugs in CT26 cells. IC50 was calculated using a sigmoidal logistic 4 parameter regression curve for all compounds.

CLAIMS

1. A compound of Formula (I):



(I)

5

or salts, hydrates or solvates thereof wherein:

- R₁ is hydrogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, -SiR₆R₇R₈, alkyl substituted with one or more SiR₆R₇R₈, -CH=NOR₁₃ or optionally R₁ and R₂ together with the atom to which they are connected form a 5, 6 or 7 membered cycloalkyl or cycloheteroalkyl ring or substituted cycloalkyl or cycloheteroalkyl ring;

10

R₂ is hydrogen, alkyl, substituted alkyl, -NO₂ or -NH₂;

R₃ is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, or -OR₉ or optionally R₃ and R₄ together with the atom to which they are connected form a 5, 6 or 7 membered cycloalkyl or cycloheteroalkyl ring or substituted cycloalkyl or

15

cycloheteroalkyl ring

R₄ is hydrogen or halogen;

R₅ is alkyl, aryl, arylalkyl, acyl or -(L)_n-P;

R₆, R₇ or R₈ are independently alkyl or arylalkyl;

- R₉ is hydrogen, alkyl, substituted alkyl, -C(O)R₁₀ -C(O)OR₁₀ or -C(O)NR₁₁R₁₂, -P or -(L)_n-P;

20

R₁₀ is alkyl, substituted alkyl, arylalkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl;

R₁₁, R₁₂ and R₁₃ are independently alkyl, substituted alkyl, arylalkyl, substituted alkyl, heteroalkyl or substituted heteroalkyl or optionally R₁₂ and R₁₃ together with the atom to which they are connected form a 5, 6 or 7 membered cycloheteroalkyl ring or substituted cycloheteroalkyl ring;

25

L is a linker;

P is a polymer; and

n is 0 or 1

provided that when R₁, R₂, R₃ and R₄ are hydrogen that R₅ is not -Ph, -C₂H₅, -C₅H₁₁, -C₆H₁₃, -C₇H₁₅, -C₈H₁₇, -C₁₅H₃₁, -C₃H₆C≡CH, -C₃H₆C≡CH, -C₃H₆C=CH₂ or -C=CH(CH₃);


5 provided that when R₁, R₃ and R₄ are hydrogen and R₂ is -NO₂ that R₅ is not -Ph or -C₅H₁₁;


provided that when R₁, R₃ and R₄ are hydrogen, and R₂ is -NH₂ that R₅ is not -Ph, -C₅H₁₁ or -C₈H₁₇;


10 provided that when R₁, R₂ and R₄ are hydrogen and R₃ is -OCH₃ that R₅ is not -C₂H₅ or -C₅H₁₁;

provided that when R₂, R₃ and R₄ are hydrogen and R₁ is -CH₃ that R₅ is not -Ph or -C₆H₁₃;

provided that when R₂, R₃ and R₄ are hydrogen and R₁ is -CH₂OH that R₅ is not -C₅H₁₁ or -C₆H₁₃;

15 provided that when R₂, R₃ and R₄ are hydrogen and R₁  is that R₅ is not -C₆H₁₃;

provided that when R₂, R₃ and R₄ are hydrogen and R₁  is that R₅ is not -C₅H₁₁;

20 provided that when R₂, R₃ and R₄ are hydrogen and R₁  is that R₅ is not -Ph;


provided that when R₁, R₂ and R₄ are hydrogen and R₃ is -C(O)R₁₀ that R₅ and R₁₀ are not identical;

provided that when R₂ and R₄ are hydrogen, R₁ is -C₂H₅ and R₃ is -C(O)R₁₀ that R₅ and R₁₀ are not identical;

25 provided that when R₂ and R₄ are hydrogen, R₁ is -C₂H₅ and R₃ is -H that R₅ is not C₁₀H₂₁; and

provided that when R_2 and R_4 are hydrogen, R_1 is $-C_2H_5$ and R_3 is $-C(O)OtBu$ that R_5 is not $C_{10}H_{21}$.


3. The compound of Claim 1 having the structure of Formula (II):



5


(II)

4. The compound of Claim 1 having the structure of Formula (III):



(III)


5. The compound of Claim 1 having the structure of Formula (IV):



10

(IV)


6. The compound of Claim 1 having the structure of Formula (V):



(V)


15

7. The compound of Claim 1 having the structure of Formula (VI):




(VI)

8. The compound of Claim 1 having the structure of Formula (VII):




(VII)

9. The compound of Claim 1 having the structure of Formula (VIII):




(VIII)

10. The compound of Claim 1 having the structure of Formula (IX):




(IX)

11. The compound of Claim 1 having the structure of Formula (X):




(X)

12. The compound of Claim 1 having the structure of Formula (XI):




(XI)

13. The compound of Claim 1 having the structure of Formula (XII):



(XII)

14. The compound of Claim 1 having the structure of Formula (XIII):




(XIII)

15. The compound of Claim 1 having the structure of Formula (XIV):


5

10




(XIV)

16. The compound of Claim 1 having the structure:




5

17. The compound of Claim 1 having the structure:



18. The compound of Claim 1 having the structure:



19. A pharmaceutical composition comprising the compound of Claim 1 and a vehicle.
20. A method of treating and/or preventing cancer in a subject comprising
- 5** administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Figure 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/021440

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61P 35/00; A61K 31/00; A61K 31/33; A61K 31/41; A61K 31/4745 (2017.01)

CPC - C07D 413/14; A61K 31/454; A61K 31/4745; A61K 2039/585; C07D 401/04 (2017.02)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	YADAV et al. QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase-I. J. Chemometrics, 27(1-2), 21-33, 2013. [retrieved on 01 June 2017]. Retrieved from the Internet. < http://onlinelibrary.wiley.com/doi/10.1002/cem.2488/abstract > see entire document	1 ----- 19, 20
Y	US 2012/0010154 A1 (DONG et al) 12 January 2012 (12.01.2012) entire document	19, 20

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

02 June 2017

Date of mailing of the international search report

07 JUL 2017

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/021440

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Extra Sheet

Claims 1, 19, and 20 have been analyzed subject to the restriction that claims read on a compound of Formula (I): or salts, hydrates, or solvates thereof wherein: R1 is hydrogen; R2 is hydrogen; R3 is hydrogen; R4 is hydrogen; R5 is alkyl, wherein the alkyl is methyl; pharmaceutical compositions thereof; and methods thereof.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1, 19, 20

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/021440

Continued from Box No. III Observations where unity of invention is lacking

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees need to be paid.

Group I+: claims 1 and 3-20 are drawn to compounds of Formula (I) or salts, hydrates, or solvates, thereof, pharmaceutical compositions thereof, and methods thereof.

The first invention of Group I+ is restricted based on the provisos that when R1, R2, R3 and R4 are hydrogen that R5 is not -Ph, -C2H5, -C5H11, -C6H13, -C7H15, -C8H17, -C15H31, -C3H6C(triple bond)CH, -C3H6C(triple bond)CH, -C3H6C=CH2 or -C=CH(CH3); provided that when R1, R3 and R4 are hydrogen and R2, is -NO2 that R5 is not Ph or -C5H11; provided that when R1, R3 and R4 are hydrogen, and R2, is -NH2 that R5 is not -Ph, -C5H11 or -C8H17; provided that when R1, R2 and R4 are hydrogen and R3 is -OCH3 that R5 is not -C2H5 or -C5H11; provided that when R2, R3 and R4 are hydrogen and R1 is -CH3 that R5 is not -Ph or -C6H13; provided that when R2, R3 and R4 are hydrogen and R1 is -CH2OH that R5 is not -C5H11 or -C6H13; provided that when R2, R3 and R4 are hydrogen and R1 is the structure shown that R5 is not -C6H13; provided that when R2, R3 and R4 are hydrogen and R1 is the structure shown that R5 is not -C5H11; provided that when R2, R3 and R4 are hydrogen and R1 is the structure shown that R5 is not -Ph; provided that when R1, R2 and R4 are hydrogen and R3 is -C(O)R10 that R5 and R10 are not identical; provided that when R2 and R4 are hydrogen, R1 is -C2H5 and R3 is -C(O)R10 that R5 and R10 are not identical; provided that when R2 and R4 are hydrogen, R1 is -C2H5 and R3 is -H that R5 is not C10H21; and provided that when R2 and R4 are hydrogen, R1, is -C2H5 and R3 is -C(O)OtBu that R5 is not C10H21; and is restricted to a compound of Formula (I): or salts, hydrates, or solvates thereof wherein: R1 is hydrogen; R2 is hydrogen; R3 is hydrogen; R4 is hydrogen; R5 is alkyl, wherein the alkyl is methyl; pharmaceutical compositions thereof; and methods thereof. It is believed that claims 1, 19, and 20 read on this first named invention and thus these claims will be searched without fee to the extent that they read on the above embodiment.

Applicant is invited to elect additional formula(e) for each additional compound to be searched in a specific combination by paying an additional fee for each set of election. Each additional elected formula(e) requires the selection of a single definition for each compound variable. An exemplary election would be a compound of Formula (I): or salts, hydrates, or solvates thereof wherein: R1 is hydrogen; R2 is -NO2; R3 is alkyl, wherein the alkyl is methyl; R4 is halogen, wherein the halogen is -F; R5 is alkyl, wherein the alkyl is methyl; pharmaceutical compositions thereof; and methods thereof. Additional formula(e) will be searched upon the payment of additional fees. Applicants must specify the claims that read on any additional elected inventions. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined.

The inventions listed in Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1, because under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons:

The Groups I+ formulae do not share a significant structural element requiring the selection of alternatives for the compound variables R1, R2, R3, R4, and R5.

The Groups I+ share the technical features of a compound having the core structure of Formula (I) or salts, hydrates or solvates thereof; a pharmaceutical composition comprising a compound, and a vehicle; a method of treating and/or preventing cancer in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound. However, these shared technical features do not represent a contribution over the prior art.

Specifically, US 2012/0010154 A1 to Dong et al. teach a compound having the core structure of Formula (I) (Para. [0315], Compound CPT;...see shown structure...); a pharmaceutical composition (Claims 22 and 23; Paras. [0362] through [0265]) comprising a compound (Claims 22 and 23), and a vehicle (Claims 22 and 23; Paras. [0362] through [0265]); a method of treating and/or preventing cancer in a subject (Claims 24 and 25) comprising administering to the subject in need thereof a therapeutically effective amount of the compound (Abstract; Claims 24 and 25; Para. [0002]; Para. [0358]).

The inventions listed in Groups I+ therefore lack unity under Rule 13 because they do not share a same or corresponding special technical feature.